Healthcare
News Category
Optimi Health Completes First Psilocybin Export to UK for Phase 2 Clinical Trial
Optimi Health Corp. has shipped naturally derived psilocybin capsules and biomass to the UK for a Phase 2 trial, marking a key step in expanding inter...
Optimi Health Advances Ibogaine Initiative, Plans GMP-Grade Production for Research and Therapeutic Programs
Optimi Health Corp. announced progress on its Ibogaine Initiative, securing naturally derived ibogaine and planning GMP-grade production of encapsulat...
Optimi Health Completes GMP Production Run of Psilocybin Drug Product for Global Markets
Optimi Health Corp. has completed a GMP production run of 5mg psilocybin capsules, using the same formulation prescribed in Australia, with product de...
Optimi Health Welcomes Australian TGA Reforms Expanding Psychedelic Therapy Access
Optimi Health praises Australia's updated psilocybin and MDMA prescribing rules, which broaden therapy teams and settings, potentially accelerating ad...
Australia’s TGA Updates Psychedelic Therapy Framework, Optimi Health Welcomes Broader Access
Optimi Health Corp. praised Australia’s TGA final recommendations that expand eligible therapy teams and treatment settings for psilocybin and MDMA, p...
NuggMD Expands to UK, Integrates Stripe to Streamline Medical Cannabis Payments
NuggMD launches in the UK and integrates Stripe for seamless payments, enhancing access for medical cannabis patients.
Jupiter Neurosciences Raises $2 Million in Registered Direct Offering
Jupiter Neurosciences closed a $2 million registered direct offering to fund its CNS pipeline, including a Phase IIa trial for Parkinson's disease and...
Report: European Cannabis Market Enters Critical Transition as Medical Access and Trade Accelerate
A new report from the Global Cannabis Network Collective and Whitney Economics highlights that Europe's cannabis market is undergoing a pivotal transf...
Europe's Cannabis Industry Enters Major Growth Phase, New Report Reveals
A new report released at Cannabis Europa 2026 indicates that Europe's cannabis economy is entering a significant growth phase, driven by expanding med...
Indiana Legislators Revisit Medical Cannabis Debate Amid Federal Uncertainty
Indiana legislators may resume discussions on medical cannabis, while state officials express uncertainty about federal action prompting policy change...
Optimi Health Corp. Highlighted in Diamond Equity Research Initiation Report for Psychedelic Manufacturing and Australia Expansion
Optimi Health Corp. was featured in a Diamond Equity Research report emphasizing its GMP-certified psychedelic manufacturing, growing traction in Aust...
House Approves Measure Allowing VA Doctors to Recommend Medical Cannabis to Veterans
The U.S. House passed an amendment to let VA physicians recommend medical marijuana in legal states, potentially expanding veteran healthcare access a...
House Approves Measure to Allow VA Doctors to Recommend Medical Cannabis to Veterans
The U.S. House passed an amendment that would permit VA physicians to recommend medical cannabis in states where it is legal, potentially expanding tr...
UC Riverside Study Sheds Light on Cannabis Users' Lower Body Weight and Reduced Diabetes Risk
A new preclinical study from UC Riverside explains why regular cannabis users often have lower body weight and lower type 2 diabetes risk, supporting ...
Study Shows Older Americans Turn to Cannabis for Relief After Conventional Treatments Fail
A federally backed study reveals that many older Americans are using cannabis to alleviate symptoms after traditional medical treatments proved ineffe...
Federal Reclassification of Medical Cannabis Reshapes Industry Outlook
A recent federal decision to reclassify medical cannabis is altering the landscape for licensed operators, drawing renewed attention from businesses a...
Cannabis Rescheduling Poised to Reshape Research and Industry, But Slow Pace and Regulatory Hurdles Remain
The potential rescheduling of cannabis in the U.S. could transform scientific research and the cannabis industry, but the pace of change is slow and d...
Silo Pharma Files Provisional Patent for Ibogaine-Based TBI and PTSD Therapeutics
Silo Pharma announced a strategic initiative to develop ibogaine-based treatments for traumatic brain injury and related conditions, filing a provisio...
Medical Cannabis Dispensary Applications Open Following DEA Regulatory Change
Businesses can begin applying for medical cannabis dispensary licenses starting April 29, following a DEA directive aligned with President Trump's ord...
DOJ Rescheduling Directive Shifts Medical Marijuana to Schedule III
A directive signed by Acting AG Todd Blanche reclassifies FDA-approved marijuana-based medications and state-licensed medical cannabis from Schedule I...
Silo Pharma Highlights Federal Support for Psychedelic Therapies, Signaling Momentum in Mental Health Treatments
Silo Pharma noted coordinated U.S. federal actions accelerating psychedelic-based therapy development for mental health and substance use disorders, c...
Dr. Sanjay Gupta’s 'Weed' Series Expands Focus on Cannabis Medicine, Impacting Tilray and Industry
Dr. Sanjay Gupta’s evolving documentary series 'Weed' highlights the intersection of cannabis, medicine, and patient experience, with implications for...